106.91 USD
+0.12 (+0.11%)
106.94 USD
+0.03 (+0.03%)
Taking everything into account, VRNA scores 3 out of 10 in our fundamental rating. VRNA was compared to 192 industry peers in the Pharmaceuticals industry. VRNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, VRNA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year VRNA has reported negative net income.
VRNA had a negative operating cash flow in the past year.
In the past 5 years VRNA always reported negative net income.
In the past 5 years VRNA always reported negative operating cash flow.
1.2 Ratios
VRNA has a Return On Assets of -14.17%. This is in the better half of the industry: VRNA outperforms 63.08% of its industry peers.
VRNA has a Return On Equity (-29.18%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.17% | ||
| ROE | -29.18% | ||
| ROIC | N/A |
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of VRNA (95.15%) is better than 96.41% of its industry peers.
VRNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRNA has more shares outstanding
Compared to 5 years ago, VRNA has more shares outstanding
Compared to 1 year ago, VRNA has a worse debt to assets ratio.
2.2 Solvency
VRNA has an Altman-Z score of 18.44. This indicates that VRNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VRNA (18.44) is better than 90.26% of its industry peers.
VRNA has a Debt/Equity ratio of 0.87. This is a neutral value indicating VRNA is somewhat dependend on debt financing.
The Debt to Equity ratio of VRNA (0.87) is worse than 71.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 18.44 |
ROIC/WACCN/A
WACC9.28%
2.3 Liquidity
VRNA has a Current Ratio of 10.71. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
VRNA has a Current ratio of 10.71. This is amongst the best in the industry. VRNA outperforms 83.08% of its industry peers.
VRNA has a Quick Ratio of 10.54. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 10.54, VRNA belongs to the top of the industry, outperforming 83.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.54 |
3. Growth
3.1 Past
VRNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.54%, which is quite impressive.
VRNA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.86% yearly.
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 57.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, VRNA will show a very strong growth in Revenue. The Revenue will grow by 123.42% on average per year.
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VRNA. In the last year negative earnings were reported.
VRNA is valuated quite expensively with a Price/Forward Earnings ratio of 48.49.
VRNA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. VRNA is cheaper than 67.18% of the companies in the same industry.
VRNA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.49 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VRNA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as VRNA's earnings are expected to grow with 64.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y73.8%
EPS Next 3Y64.23%
5. Dividend
5.1 Amount
No dividends for VRNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
106.91
+0.12 (+0.11%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners80.77%
Inst Owner Change5.81%
Ins Owners4.64%
Ins Owner Change-1851.26%
Market Cap9.19B
Revenue(TTM)221.67M
Net Income(TTM)-81.19M
Analysts68.89
Price Target108.43 (1.42%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)75.16%
Min EPS beat(2)-4.58%
Max EPS beat(2)154.9%
EPS beat(4)1
Avg EPS beat(4)26.61%
Min EPS beat(4)-34.07%
Max EPS beat(4)154.9%
EPS beat(8)3
Avg EPS beat(8)-13.52%
EPS beat(12)4
Avg EPS beat(12)-12.45%
EPS beat(16)8
Avg EPS beat(16)2.57%
Revenue beat(2)2
Avg Revenue beat(2)24.91%
Min Revenue beat(2)9.73%
Max Revenue beat(2)40.08%
Revenue beat(4)4
Avg Revenue beat(4)58.05%
Min Revenue beat(4)8.73%
Max Revenue beat(4)173.67%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.55%
EPS NY rev (1m)2.01%
EPS NY rev (3m)147.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 48.49 | ||
| P/S | 41.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.04 | ||
| P/tB | 33.1 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.99
EYN/A
EPS(NY)2.2
Fwd EY2.06%
FCF(TTM)-0.86
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS2.58
BVpS3.24
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.17% | ||
| ROE | -29.18% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.15% | ||
| FCFM | N/A |
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.87 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 96.14% | ||
| Cap/Sales | 0.48% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.71 | ||
| Quick Ratio | 10.54 | ||
| Altman-Z | 18.44 |
F-Score4
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
EPS Next Y123.97%
EPS Next 2Y73.8%
EPS Next 3Y64.23%
EPS Next 5Y57.72%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1008.75%
Revenue Next 2Y342.34%
Revenue Next 3Y211.05%
Revenue Next 5Y123.42%
EBIT growth 1Y57.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.44%
EBIT Next 3Y118.37%
EBIT Next 5YN/A
FCF growth 1Y-39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.98%
OCF growth 3YN/A
OCF growth 5YN/A
VERONA PHARMA PLC - ADR / VRNA FAQ
Can you provide the ChartMill fundamental rating for VERONA PHARMA PLC - ADR?
ChartMill assigns a fundamental rating of 3 / 10 to VRNA.
Can you provide the valuation status for VERONA PHARMA PLC - ADR?
ChartMill assigns a valuation rating of 2 / 10 to VERONA PHARMA PLC - ADR (VRNA). This can be considered as Overvalued.
How profitable is VERONA PHARMA PLC - ADR (VRNA) stock?
VERONA PHARMA PLC - ADR (VRNA) has a profitability rating of 2 / 10.
Can you provide the financial health for VRNA stock?
The financial health rating of VERONA PHARMA PLC - ADR (VRNA) is 5 / 10.